Overview

A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the dose limiting toxicity (DLT) of BMS-582664 and the maximum tolerated dose(MTD) in subjects with advanced or metastatic solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb